Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
12.14.2007
NICE proposes new risk-sharing agreement for Novatis' eye drug Lucentis
The UK NICE has proposed a cap for the dosing of Lucentis, an eye drug from Novartis Pharma, to 14 shots per eye while additional dose requirements would be at the cost of Novartis.
No comments:
Post a Comment